FDA Medical Device Launch Guide: 510(k), De Novo & PMA (2026)
Launching a medical device in the United States is not a single FDA event. It is a coordinated sequence of regulatory, quality, clinical, commercial, and postmarket decisions.
The first thing to fix is terminology: “FDA registered” is not a market-authorization claim. FDA states that establishment registration and device listing do not mean a device is approved, cleared, or authorized. FDA also does not issue device-registration certificates.
So the right launch question is not, “How do we launch an FDA-registered device?” It is:
What regulatory pathway applies to this device, what evidence and quality-system requirements follow from that pathway, and how do we build the commercial plan around the claims we will actually be allowed to make?
This guide is educational and does not replace regulatory or legal advice for a specific device.
1. Start With Classification
FDA classifies medical devices based on risk and the regulatory controls needed to provide reasonable assurance of safety and effectiveness.
At a high level:
- Class I: generally lower risk. Many are exempt from premarket notification, although general controls and other requirements may still apply.
- Class II: generally moderate risk. Many require a 510(k), although some are exempt.
- Class III: generally highest risk. Many require Premarket Approval, or PMA.
Classification should be based on the device type, intended use, indications, technological characteristics, applicable regulation, and available predicates, not on what pathway appears commercially convenient.
Use FDA's Product Classification database, device-specific regulations and guidance, and regulatory counsel when the pathway is uncertain.
2. Understand the Three Main Premarket Pathways
510(k) Premarket Notification
A 510(k) is generally used when a legally marketed predicate exists and the new device can be shown to be substantially equivalent to that predicate.
FDA describes substantial equivalence as demonstrating that the new device has the same intended use and either the same technological characteristics or different characteristics that do not raise different questions of safety and effectiveness and are supported by appropriate data.
A strong 510(k) strategy begins with predicate selection, not submission formatting.
Evaluate:
- intended use
- indications for use
- technological characteristics
- performance testing
- biocompatibility where applicable
- software and cybersecurity where applicable
- electrical safety and EMC where applicable
- sterilization and shelf life where applicable
- human factors where applicable
- labeling
De Novo Classification
De Novo is intended for certain novel low-to-moderate-risk devices for which there is no legally marketed predicate suitable for a 510(k).
If granted, FDA creates a new device classification. Future devices of the same type may then be able to use that classification as the basis for a 510(k), depending on the facts.
Do not treat De Novo as simply “510(k) without a predicate.” The company must build a persuasive risk-control case showing that general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness.
Premarket Approval, PMA
PMA is FDA's most rigorous medical-device premarket submission pathway and is generally associated with high-risk Class III devices.
The evidentiary burden is different from substantial equivalence. FDA evaluates whether the application contains sufficient valid scientific evidence to provide reasonable assurance that the device is safe and effective for its intended use.
Clinical evidence, manufacturing information, labeling, inspections, and quality-system readiness can all become central to a PMA launch.
Primary FDA overview: Medical Device Safety and the 510(k) Clearance Process.
3. Registration and Listing Come After the Regulatory Question Is Solved
FDA's current “How to Study and Market Your Device” guidance makes the sequence clear. When a device requires premarket review, the manufacturer generally must wait for the applicable FDA clearance or approval before registering the establishment and listing the device for commercial distribution.
Registration and listing are important regulatory obligations, but they are not proof of FDA endorsement.
Avoid:
- “FDA certified”
- “FDA registration certificate” language implying agency endorsement
- using the FDA logo in private marketing
- using “FDA registered” as a substitute for the actual device status
Use the exact status that applies to the product.
Primary FDA source: FDA: Are There “FDA Registered” or “FDA Certified” Medical Devices?
4. Get the Intended Use and Indications Right Before You Write Marketing
The commercial team should not invent a broad market promise and ask regulatory to “approve the copy” later.
The better sequence is:
Intended use → indications → evidence → claims → positioning → channel execution.
For PMA devices, FDA specifically ties indications for use to the nonclinical and clinical evidence in the application. For other pathways, intended use and indications are still foundational to how the product is classified, reviewed, labeled, and promoted.
Create a plain-English regulatory brief for marketing that includes:
- device status
- intended use
- indications for use
- patient population
- material limitations
- key warnings and contraindications
- supported performance claims
- unsupported or prohibited claims
5. Use the Q-Submission Program Strategically
For novel technology, uncertain testing plans, clinical-study questions, or other high-impact issues, early FDA interaction can reduce expensive rework.
FDA's Q-Submission program provides mechanisms for companies to obtain agency feedback before certain formal submissions. FDA also now supports the PreSTAR electronic template for several Q-Submission types.
Do not use a Q-Sub to ask FDA to develop the regulatory strategy for the company. Bring a proposed approach and ask targeted questions.
Good questions are specific:
- Does the proposed test method address the identified risk?
- Is the proposed clinical endpoint appropriate for the intended indication?
- Does FDA agree with the proposed predicate rationale?
- Is the proposed human-factors validation plan adequate?
Current FDA source: FDA eSTAR and PreSTAR Program.
6. Build the Quality System for 2026, Not 2024
This is one of the biggest updates missing from older medical-device launch guides.
On February 2, 2026, FDA's Quality Management System Regulation, or QMSR, became effective. The revised 21 CFR Part 820 incorporates ISO 13485:2016 by reference and replaces the old Quality System Regulation framework.
FDA also stopped using the old Quality System Inspection Technique, QSIT, and moved to a new inspection process aligned with QMSR.
That means a 2026 launch plan should not talk about FDA “moving toward” ISO 13485. That transition has happened.
Quality-system readiness should address the requirements applicable to the device and manufacturer, including areas such as:
- design and development
- risk management
- supplier controls
- document and record control
- production and process controls
- complaint handling
- nonconformity and corrective action
- management review
- internal audits
- training and competence
FDA also states that under QMSR, investigators may review certain records such as management reviews, quality audits, and supplier-audit reports that previously had inspection exemptions under the old rule.
Primary FDA source: Quality Management System Regulation (QMSR).
7. Build the Evidence Plan Around the Device's Risks
There is no universal test list for every device.
Depending on the product, evidence may include:
- bench performance
- mechanical testing
- electrical safety and EMC
- biocompatibility
- sterilization validation
- packaging validation
- shelf life
- software verification and validation
- cybersecurity documentation
- human factors and usability
- animal testing
- clinical data
The mistake is either over-testing because “FDA might want it” or under-testing because a founder assumes the device is simple.
Connect each test to a specific design requirement, hazard, performance claim, or regulatory expectation.
8. Do Not Assume Every Device Needs a Clinical Trial
Clinical-data requirements depend on the pathway, device type, risk, novelty, existing evidence, and questions that nonclinical testing cannot answer.
Some 510(k)s are supported primarily by nonclinical performance testing. Other 510(k)s require clinical evidence. De Novo requests may require clinical data. PMAs commonly depend heavily on clinical evidence.
If a significant-risk clinical investigation is planned, the Investigational Device Exemption framework may apply.
Clinical strategy should be resolved early enough that the company does not discover late in development that its commercial claims require evidence it never collected.
9. Build the Commercial Plan Before Market Authorization
Regulatory work and go-to-market work should proceed in parallel, but with a hard boundary: the company should not commercially promote a device in a way that violates applicable premarket restrictions or overstates its status.
Before launch, leadership should already know:
- who uses the device
- who buys it
- who controls the budget
- who can block adoption
- how reimbursement affects demand
- what workflow change is required
- what proof clinicians need
- what proof procurement needs
- what proof finance needs
- how long implementation takes
For hospital and health-system devices, the funnel may look more like:
Awareness → clinical champion → evaluation → security/IT → value analysis → procurement → contracting → implementation → adoption.
Lead volume tells you very little if the product stalls in procurement or never gets adopted after purchase.
10. Create a Claims Matrix Before Launch
FDA's labeling rules prohibit false or misleading labeling. FTC rules also matter for advertising claims.
Create a claims matrix that gives commercial teams one source of truth:
- claim
- exact evidence supporting it
- regulatory-status language
- required qualification
- approved channels
- prohibited variants
- owner
- last review date
Review the whole commercial system:
Website → ads → sales deck → demo → conference booth → distributor materials → testimonials → investor deck.
A safe homepage does not help if the field-sales deck makes a broader claim.
See FDA Medical Device Marketing Rules for CEOs.
11. Launch Operations Matter as Much as Marketing
Before the first commercial order, confirm that the company can actually support the product.
Launch readiness should cover:
- manufacturing capacity
- supplier continuity
- labeling and packaging
- distribution
- installation
- training
- service and maintenance
- complaint intake
- adverse-event escalation
- field actions
- software updates where applicable
- customer support
Commercial demand that outruns operational readiness can create quality problems very quickly.
12. Postmarket Compliance Starts on Day One
Clearance, classification, or approval is not the finish line.
Manufacturers may have ongoing obligations involving complaint handling, Medical Device Reporting, corrections and removals, recalls, quality-system records, and other postmarket controls depending on the device and circumstances.
Build escalation rules before the first complaint arrives.
Marketing and customer-service teams should be trained to recognize information that may need to enter the quality system rather than treating every complaint as merely a customer-experience ticket.
13. The 2026 Medical Device Launch Checklist
- Confirm device classification.
- Confirm whether the device is exempt or requires 510(k), De Novo, PMA, or another pathway.
- Define intended use and indications.
- Select and document the regulatory strategy.
- Use Q-Sub or other FDA interaction when the unresolved question is material.
- Build the QMS around the now-effective QMSR and applicable ISO 13485:2016 requirements.
- Map device risks to verification, validation, and clinical evidence.
- Prepare accurate labeling.
- Build a claims matrix before commercial launch.
- Map the user, clinical champion, buyer, procurement path, and reimbursement environment.
- Prepare manufacturing, distribution, training, and service operations.
- Register the establishment and list the device when required and appropriate in the regulatory sequence.
- Launch only with accurate regulatory-status language.
- Track adoption, not only leads and sales.
- Operate complaint, MDR, correction/removal, and quality processes from day one.
Primary FDA Sources
- How to Study and Market Your Device
- Device Approvals and Clearances
- Registered vs Cleared vs Approved Devices
- Quality Management System Regulation
- Labeling Requirements and Misbranding
The Bottom Line
The strongest medical-device launch is not the one that races from prototype to promotion fastest.
It is the one where classification, pathway, evidence, quality system, labeling, claims, operations, and commercial strategy all agree with one another.
That alignment reduces rework and creates a much stronger foundation for adoption after the regulatory milestone is reached.
For the commercial side, see 7 Medical Device Marketing Mistakes Startups Make.
